AVTE NASDAQ
Aerovate Therapeutics, Inc.
1W: -3.2%
1M: +5.9%
3M: +4.3%
1Y: -87.4%
3Y: -82.0%
$2.68
Last traded 2025-04-28 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$114M
-52.2% ▼
Net Income
-$127M
-83.0% ▼
EPS (Diluted)
$-3193.30
-130773.0% ▼
EBITDA
-$114M
-52.8% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $68K | $96K | $0 | $0 |
| Gross Profit | -$15K | -$68K | -$96K | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $15M | $39M | $64M | $53M | $93M |
| SG&A Expenses | $8M | $15M | $17M | $21M | $20M |
| Operating Expenses | $23M | $53M | $81M | $75M | $114M |
| Operating Income | -$23M | -$53M | -$81M | -$75M | -$114M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $65K | $0 | $0 | $0 | $0 |
| Income Before Tax | -$23M | -$51M | -$75M | -$70M | -$127M |
| Tax Expense | $3K | $25K | $56K | $55K | -$58K |
| Net Income | -$23M | -$52M | -$76M | -$70M | -$127M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-1.87 | $-2.10 | $-2.87 | $-2.44 | $-3193.30 |
| EBITDA | -$23M | -$53M | -$81M | -$74M | -$114M |
| Shares Outstanding | 24M | 24M | 26M | 29M | 31M |